Rheumatology Advisor

Efgartigimod Alfa–Hyaluronidase Improves Ocular Myasthenia Gravis Symptoms

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.
Healio

Keep hyaluronidase on hand to address injection filler complications

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — Hypersensitivity reactions to injection fillers are rare and unpredictable, but when they occur, ...
Seeking Alpha

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Nasdaq

argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized ...

Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Pharmabiz

US FDA approves Janssen Biotech’s teclistamab in combo with daratumumab hyaluronidase-fihj, Tec-Dara under the National Priority Voucher Programme

Silver Spring, Maryland Saturday, March 7, 2026, 11:00 Hrs [IST] ...
Benzinga.com

Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis

The FDA has approved Argenx SE's (NASDAQ:ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult ...
MedPage Today

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...
Seeking Alpha

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ non-small cell lung cancer 1,3-6 HORSHAM, Pa., Feb. 17, 2026 /PRNewswire/ -- Johnson & ...
Medscape

Hyaluronidase Speeds Up Insulin Absorption From Skin

October 9, 2012 (Berlin, Germany) — In a randomized, double-blind, comparator-controlled, 2-way crossover trial, 2 rapid-acting insulin analogs (lispro or aspart) formulated with recombinant human ...

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and ...